Literature DB >> 19339092

Kidney pathological changes in metabolic syndrome: a cross-sectional study.

Mariam P Alexander1, Tejas V Patel, Youssef M K Farag, Adriana Florez, Helmut G Rennke, Ajay K Singh.   

Abstract

BACKGROUND: The worldwide prevalence of metabolic syndrome is increasing and has been associated with chronic kidney disease. Kidney pathological findings in patients with metabolic syndrome have not been well described, as was explored in this study. STUDY
DESIGN: Cross-sectional study. SETTING & PARTICIPANTS: We retrospectively screened clinical information for 146 patients who underwent elective nephrectomy for renal cell carcinoma between January 2005 and March 2007 at Brigham and Women's Hospital, Boston, MA. Twelve patients with metabolic syndrome were identified. Twelve age- and sex-matched patients who did not have any of the criteria for metabolic syndrome were used as controls. PREDICTOR: Presence of metabolic syndrome defined by using Adult Treatment Panel III criteria. OUTCOMES: Histological characteristics in each group, decrease in kidney function at 1-year follow-up. MEASUREMENTS: Two pathologists blinded to the clinical diagnosis independently evaluated nephrectomy specimens using Banff criteria to objectively assess histological characteristics.
RESULTS: Baseline characteristics were similar between the 2 groups. On histopathologic examination, patients with metabolic syndrome compared with controls had a greater prevalence of tubular atrophy (P = 0.006), interstitial fibrosis (P = 0.001), and arterial sclerosis (P = 0.001), suggesting microvascular disease. Patients with metabolic syndrome had greater global (P = 0.04) and segmental glomerulosclerosis (P = 0.05). Glomerular volume and cross-sectional surface area were not different. The combined end point of tubular atrophy greater than 5%, interstitial fibrosis greater than 5%, and presence of arterial sclerosis was more prevalent in patients with metabolic syndrome (P = 0.003; odds ratio, 33; confidence interval, 2.9 to 374.3) than controls. After 1 year, estimated glomerular filtration rate was significantly lower in patients with metabolic syndrome compared with controls (P = 0.03). LIMITATIONS: Small sample size, retrospective design.
CONCLUSIONS: We report a high prevalence of microvascular disease in patients with metabolic syndrome. There was a steeper decrease in kidney function over time in patients with metabolic syndrome, suggesting limited renal reserve. Aggressive screening and management may be warranted in patients with metabolic syndrome to protect kidney function.

Entities:  

Mesh:

Year:  2009        PMID: 19339092      PMCID: PMC2765403          DOI: 10.1053/j.ajkd.2009.01.255

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  49 in total

Review 1.  The metabolic syndrome: prevalence in worldwide populations.

Authors:  Adrian J Cameron; Jonathan E Shaw; Paul Z Zimmet
Journal:  Endocrinol Metab Clin North Am       Date:  2004-06       Impact factor: 4.741

Review 2.  Modulation of glomerular sclerosis and interstitial fibrosis by native and modified lipoproteins.

Authors:  H J Gröne; J Hohbach; E F Gröne
Journal:  Kidney Int Suppl       Date:  1996-05       Impact factor: 10.545

Review 3.  Banting lecture 1988. Role of insulin resistance in human disease.

Authors:  G M Reaven
Journal:  Diabetes       Date:  1988-12       Impact factor: 9.461

Review 4.  Nephron mass as a risk factor for progression of renal disease.

Authors:  B M Brenner; H S Mackenzie
Journal:  Kidney Int Suppl       Date:  1997-12       Impact factor: 10.545

5.  Tubulointerstitial lesions in non-insulin dependent diabetes mellitus.

Authors:  M Ueno; S Kawashima; S Nishi; H Shimada; R Karasawa; Y Suzuki; Y Maruyama; M Arakawa
Journal:  Kidney Int Suppl       Date:  1997-12       Impact factor: 10.545

Review 6.  Mediators of diabetic renal disease: the case for tgf-Beta as the major mediator.

Authors:  Fuad N Ziyadeh
Journal:  J Am Soc Nephrol       Date:  2004-01       Impact factor: 10.121

7.  Increasing prevalence of the metabolic syndrome among u.s. Adults.

Authors:  Earl S Ford; Wayne H Giles; Ali H Mokdad
Journal:  Diabetes Care       Date:  2004-10       Impact factor: 19.112

Review 8.  Tubulointerstitial disease: role of ischemia and microvascular disease.

Authors:  Takahiko Nakagawa; Duk-Hee Kang; Ryuji Ohashi; Shin-ichi Suga; Jaime Herrera-Acosta; Bernardo Rodriguez-Iturbe; Richard J Johnson
Journal:  Curr Opin Nephrol Hypertens       Date:  2003-05       Impact factor: 2.894

9.  Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease.

Authors:  Marcello Tonelli; Lemuel Moyé; Frank M Sacks; Thom Cole; Gary C Curhan
Journal:  J Am Soc Nephrol       Date:  2003-06       Impact factor: 10.121

10.  The metabolic syndrome and chronic kidney disease in U.S. adults.

Authors:  Jing Chen; Paul Muntner; L Lee Hamm; Daniel W Jones; Vecihi Batuman; Vivian Fonseca; Paul K Whelton; Jiang He
Journal:  Ann Intern Med       Date:  2004-02-03       Impact factor: 25.391

View more
  33 in total

Review 1.  The kidney in obesity.

Authors:  Josep Redon; Empar Lurbe
Journal:  Curr Hypertens Rep       Date:  2015-06       Impact factor: 5.369

2.  Metabolic syndrome, ESRD, and death in CKD.

Authors:  Sankar D Navaneethan; Jesse D Schold; John P Kirwan; Susana Arrigain; Stacey E Jolly; Emilio D Poggio; Srinivasan Beddhu; Joseph V Nally
Journal:  Clin J Am Soc Nephrol       Date:  2013-02-14       Impact factor: 8.237

3.  Chronic kidney disease and end-stage renal disease in the elderly population: current prevalence, future projections, and clinical significance.

Authors:  Lesley A Stevens; Gautham Viswanathan; Daniel E Weiner
Journal:  Adv Chronic Kidney Dis       Date:  2010-07       Impact factor: 3.620

Review 4.  Kidney aging--inevitable or preventable?

Authors:  Devasmita Choudhury; Moshe Levi
Journal:  Nat Rev Nephrol       Date:  2011-08-09       Impact factor: 28.314

Review 5.  Metabolic syndrome and chronic kidney disease: Current status and future directions.

Authors:  G V Ramesh Prasad
Journal:  World J Nephrol       Date:  2014-11-06

6.  Larger Nephron Size and Nephrosclerosis Predict Progressive CKD and Mortality after Radical Nephrectomy for Tumor and Independent of Kidney Function.

Authors:  Aleksandar Denic; Hisham Elsherbiny; Aidan F Mullan; Bradley C Leibovich; R Houston Thompson; Luisa Ricaurte Archila; Ramya Narasimhan; Walter K Kremers; Mariam P Alexander; John C Lieske; Lilach O Lerman; Andrew D Rule
Journal:  J Am Soc Nephrol       Date:  2020-09-16       Impact factor: 10.121

7.  World Congress on the Insulin Resistance Syndrome, 2009: the kidney, the liver, and insulin resistance.

Authors:  Zachary T Bloomgarden
Journal:  Diabetes Care       Date:  2010-09       Impact factor: 19.112

Review 8.  Obesity and metabolic syndrome in kidney transplantation.

Authors:  Heather LaGuardia; Rubin Zhang
Journal:  Curr Hypertens Rep       Date:  2013-06       Impact factor: 5.369

9.  Association of metabolic syndrome with kidney function and histology in living kidney donors.

Authors:  Y Ohashi; G Thomas; S Nurko; B Stephany; R Fatica; A Chiesa; A D Rule; T Srinivas; J D Schold; S D Navaneethan; E D Poggio
Journal:  Am J Transplant       Date:  2013-07-19       Impact factor: 8.086

Review 10.  Impact of treating the metabolic syndrome on chronic kidney disease.

Authors:  Varun Agrawal; Aashish Shah; Casey Rice; Barry A Franklin; Peter A McCullough
Journal:  Nat Rev Nephrol       Date:  2009-07-28       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.